riluzole has been researched along with Depression in 13 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Riluzole's therapeutic potential for treating mood disorders may involve GLT-1 and BDNF, and we suggest this protocol could be used to further characterize its precise long-term biochemical mechanisms of action in animal models of depression." | 7.78 | Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice. ( Espitia, JW; Gourley, SL; Sanacora, G; Taylor, JR, 2012) |
| "Riluzole treatment also reversed CUS-induced reductions in glial metabolism and GFAP mRNA expression." | 5.36 | Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. ( Banasr, M; Behar, KL; Chowdhury, GM; Duman, RS; Newton, SS; Sanacora, G; Terwilliger, R, 2010) |
| " Veterans and active duty service members with combat-related PTSD (per the Clinician Administered PTSD Scale [CAPS]) who were not responsive to SSRI or SNRI pharmacotherapy were randomized to 8-week augmentation with a starting dose of 100 mg/d of riluzole (n = 36) or placebo (n = 38) and assessed weekly for PTSD symptoms, anxiety, depression, disability, and side effects." | 5.34 | Randomized Controlled Trial of Riluzole Augmentation for Posttraumatic Stress Disorder: Efficacy of a Glutamatergic Modulator for Antidepressant-Resistant Symptoms. ( Aliaga, P; Bartolanzo, D; Benedek, DM; Dempsey, CL; Possemato, K; Spangler, PT; Vythilingam, M; West, JC; Zarate, C, 2020) |
| "The N-methyl-D-aspartate antagonist ketamine has rapid antidepressant effects in patients with treatment-resistant major depression (TRD); these effects have been reported to last for 1 week in some patients." | 5.16 | Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. ( Brutsche, N; Diazgranados, N; Franco-Chaves, J; Henter, ID; Ibrahim, L; Kronstein, P; Luckenbaugh, DA; Manji, HK; Moaddel, R; Wainer, I; Zarate, CA, 2012) |
| "Riluzole's therapeutic potential for treating mood disorders may involve GLT-1 and BDNF, and we suggest this protocol could be used to further characterize its precise long-term biochemical mechanisms of action in animal models of depression." | 3.78 | Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice. ( Espitia, JW; Gourley, SL; Sanacora, G; Taylor, JR, 2012) |
| "Riluzole is a glutamate regulator and effective in treatment of neuropsychiatric conditions." | 2.90 | Riluzole for treatment of men with methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial. ( Akhondzadeh, S; Bidaki, R; Farahzadi, MH; Moazen-Zadeh, E; Razaghi, E; Zarrindast, MR, 2019) |
| "Riluzole has no negative effect on oxaliplatin antiproliferative capacity in human colorectal cancer cells and on its anticancer effect in a mouse model of colorectal cancer." | 1.48 | Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin. ( Aissouni, Y; Authier, N; Balayssac, D; Barriere, DA; Busserolles, J; Eschalier, A; Giraudet, F; Kerckhove, N; Lamoine, S; Lazdunski, M; Lolignier, S; Meleine, M; Pereira, V; Poupon, L; Prival, L; Richard, D, 2018) |
| "Riluzole treatment also reversed CUS-induced reductions in glial metabolism and GFAP mRNA expression." | 1.36 | Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. ( Banasr, M; Behar, KL; Chowdhury, GM; Duman, RS; Newton, SS; Sanacora, G; Terwilliger, R, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Vivier, D | 1 |
| Bennis, K | 1 |
| Lesage, F | 1 |
| Ducki, S | 1 |
| Spangler, PT | 1 |
| West, JC | 1 |
| Dempsey, CL | 1 |
| Possemato, K | 1 |
| Bartolanzo, D | 1 |
| Aliaga, P | 1 |
| Zarate, C | 1 |
| Vythilingam, M | 1 |
| Benedek, DM | 1 |
| Poupon, L | 1 |
| Lamoine, S | 1 |
| Pereira, V | 1 |
| Barriere, DA | 1 |
| Lolignier, S | 1 |
| Giraudet, F | 1 |
| Aissouni, Y | 1 |
| Meleine, M | 1 |
| Prival, L | 1 |
| Richard, D | 1 |
| Kerckhove, N | 1 |
| Authier, N | 1 |
| Balayssac, D | 1 |
| Eschalier, A | 1 |
| Lazdunski, M | 1 |
| Busserolles, J | 1 |
| Farahzadi, MH | 1 |
| Moazen-Zadeh, E | 1 |
| Razaghi, E | 1 |
| Zarrindast, MR | 1 |
| Bidaki, R | 1 |
| Akhondzadeh, S | 1 |
| Scott, K | 1 |
| Shannon, R | 1 |
| Roche-Green, A | 1 |
| Searcy, R | 1 |
| Woolyhand, G | 1 |
| Meeks, G | 1 |
| Schuh, M | 1 |
| Nourbakhsh, B | 1 |
| Julian, L | 1 |
| Waubant, E | 1 |
| Banasr, M | 1 |
| Chowdhury, GM | 1 |
| Terwilliger, R | 1 |
| Newton, SS | 1 |
| Duman, RS | 1 |
| Behar, KL | 1 |
| Sanacora, G | 3 |
| Mathew, SJ | 1 |
| Murrough, JW | 1 |
| aan het Rot, M | 1 |
| Collins, KA | 1 |
| Reich, DL | 1 |
| Charney, DS | 1 |
| Valentine, GW | 1 |
| Gourley, SL | 1 |
| Espitia, JW | 1 |
| Taylor, JR | 1 |
| Ibrahim, L | 1 |
| Diazgranados, N | 1 |
| Franco-Chaves, J | 1 |
| Brutsche, N | 1 |
| Henter, ID | 1 |
| Kronstein, P | 1 |
| Moaddel, R | 1 |
| Wainer, I | 1 |
| Luckenbaugh, DA | 1 |
| Manji, HK | 1 |
| Zarate, CA | 1 |
| Bonelli, RM | 1 |
| Hofmann, P | 1 |
| Landwehrmeyer, GB | 1 |
| Dubois, B | 1 |
| de Yébenes, JG | 1 |
| Kremer, B | 1 |
| Gaus, W | 1 |
| Kraus, PH | 1 |
| Przuntek, H | 1 |
| Dib, M | 1 |
| Doble, A | 1 |
| Fischer, W | 1 |
| Ludolph, AC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Riluzole for PTSD: Efficacy of a Glutamatergic Modulator as Augmentation Treatment for Posttraumatic Stress Disorder[NCT02155829] | Phase 1/Phase 2 | 75 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| Using Patient-Reported Outcomes To Improve the Care of People With Multiple Sclerosis: A Randomized Trial[NCT04979546] | 356 participants (Anticipated) | Interventional | 2021-11-04 | Recruiting | |||
| MS Wellness Navigator: The Effect of Nurse Practitioner (NP-led) Care on Mood, Anxiety and Health Related Quality of Life in People With Multiple Sclerosis - A Randomized Trial[NCT04388592] | 248 participants (Actual) | Interventional | 2017-04-01 | Completed | |||
| Continuation Riluzole in the Prevention of Relapse Following Ketamine in Major Depression[NCT00419003] | Phase 4 | 26 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"CAPS is a 30-item structured interview that can be used to make current (past month) diagnoses of PTSD, make lifetime diagnoses of PTSD, and assess PTSD symptoms over the past week.~A summed score of 17 items:~Minimum Score: 0 (no symptoms)~Maximum Score: 136 (very severe symptoms)~Subscales:~Subscale B (re-experiencing): items 1-5, a score of 0-40. Subscale C (avoidance): items 6-12, a score of 0-56. Subscale D (hyperarousal): items 13-17, a score of 0-40.~CAPS scores were measured at baseline, mid-treatment, and post-treatment. For outcome analyses, differences between pre-treatment and post-treatment scores were used." (NCT02155829)
Timeframe: Week 1 and 8
| Intervention | score on a scale (Mean) |
|---|---|
| Riluzole | -21.1 |
| Placebo | -16.7 |
"Subscale D (items 13-17 on the CAPS-IV) measures Hyperarousal symptoms of PTSD~Scoring: A sum of items 13-17. Minimum: 0 (no symptoms) Maximum: 40 (very severe symptoms)~CAPS-D scores were measured at baseline, mid-treatment, and post-treatment. For outcome analyses, differences between pre-treatment and post-treatment scores were used." (NCT02155829)
Timeframe: Week 1 and 8
| Intervention | score on a scale (Mean) |
|---|---|
| Riluzole | -6.8 |
| Placebo | -3.7 |
"A 14-item clinician-administered assessment measuring anxiety symptoms.~Scoring: A sum of all 14 items. Minimum: 0 (no symptoms) Maximum: 56 (very severe symptoms)~HAM-A scores were measured at baseline, mid-treatment, and post-treatment. For outcome analyses, differences between pre-treatment and post-treatment scores were used." (NCT02155829)
Timeframe: Week 1 and 8
| Intervention | score on a scale (Mean) |
|---|---|
| Riluzole | -7.8 |
| Placebo | -6.7 |
"A ten-item diagnostic questionnaire to measure the severity of depressive episodes.~Scoring: A sum of all 10 items. Minimum: 0 (no symptoms) Maximum: 60 (very severe symptoms)~MADRS scores were measured at every study visit. For outcome analyses, differences between pre-treatment and post-treatment scores were used." (NCT02155829)
Timeframe: Week 1 and 8
| Intervention | score on a scale (Mean) |
|---|---|
| Riluzole | -7.9 |
| Placebo | -8.2 |
"A 17-item self-report measure used to assess PTSD symptoms related to a specific traumatic event.~Scoring: A sum of all 17 items. Minimum: 17 (no symptoms) Maximum: 85 (very severe symptoms)~PCL-S scores were measured at every study visit. For outcome analyses, differences between pre-treatment and post-treatment scores were used." (NCT02155829)
Timeframe: Week 1 and 8
| Intervention | score on a scale (Mean) |
|---|---|
| Riluzole | -15.4 |
| Placebo | -14.5 |
"The subscale D (items 13-17 on the PCL) measures hyperarousal symptoms of PTSD. Scoring: A sum of items 13 to 17. Minimum: 5 (no symptoms) Maximum: 25 (very severe symptoms)~PCL-D scores were measured at baseline, mid-treatment, and post-treatment. For outcome analyses, differences between pre-treatment and post-treatment scores were used." (NCT02155829)
Timeframe: Week 1 and week 8
| Intervention | score on a scale (Mean) |
|---|---|
| Riluzole | -5.9 |
| Placebo | -3.4 |
"A 3-item self-report measure to assess functional impairment in work/school, social, and family life.~Scoring: A sum of all 3 items. Minimum: 0 (no symptoms) Maximum: 30 (very severe symptoms)~SDS scores were measured at baseline, mid-treatment, and post-treatment. For outcome analyses, differences between pre-treatment and post-treatment scores were used." (NCT02155829)
Timeframe: Week 1 and 8
| Intervention | score on a scale (Mean) |
|---|---|
| Riluzole | -6.3 |
| Placebo | -5.7 |
Montgomery-Asberg Depression Rating Scale, each of the ten items can be scored from 0 (absence of symptoms to 6 most severe) and has a total score range of 0-60. A lower score on a MADRS indicates a less severe depression. The primary outcome for the initial phase of the trial was the 24-h MADRS score, which included all 10 MADRS items. (NCT00419003)
Timeframe: 24 Hours
| Intervention | scores on a scale (Mean) |
|---|---|
| Riluzole Group | 24.4 |
| Placebo | 22.0 |
2 reviews available for riluzole and Depression
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc | 2016 |
A systematic review of the treatment studies in Huntington's disease since 1990.
Topics: Amantadine; Antipsychotic Agents; Chorea; Depression; Humans; Huntington Disease; Neuroprotective Ag | 2007 |
6 trials available for riluzole and Depression
| Article | Year |
|---|---|
Randomized Controlled Trial of Riluzole Augmentation for Posttraumatic Stress Disorder: Efficacy of a Glutamatergic Modulator for Antidepressant-Resistant Symptoms.
Topics: Adult; Anxiety; Depression; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Excitato | 2020 |
Riluzole for treatment of men with methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Amphetamine-Related Disorders; Craving; Depression; Double-Blind Method; Ex | 2019 |
Fatigue and depression predict quality of life in patients with early multiple sclerosis: a longitudinal study.
Topics: Adult; Cross-Sectional Studies; Depression; Fatigue; Female; Humans; Longitudinal Studies; Male; Mid | 2016 |
Fatigue and depression predict quality of life in patients with early multiple sclerosis: a longitudinal study.
Topics: Adult; Cross-Sectional Studies; Depression; Fatigue; Female; Humans; Longitudinal Studies; Male; Mid | 2016 |
Fatigue and depression predict quality of life in patients with early multiple sclerosis: a longitudinal study.
Topics: Adult; Cross-Sectional Studies; Depression; Fatigue; Female; Humans; Longitudinal Studies; Male; Mid | 2016 |
Fatigue and depression predict quality of life in patients with early multiple sclerosis: a longitudinal study.
Topics: Adult; Cross-Sectional Studies; Depression; Fatigue; Female; Humans; Longitudinal Studies; Male; Mid | 2016 |
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.
Topics: Adult; Aged; Depression; Drug Interactions; Drug Resistance; Excitatory Amino Acid Antagonists; Fema | 2010 |
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Depression; Double-Blind Method; Excitatory Amino Acid Antagonists; Female; | 2012 |
Riluzole in Huntington's disease: a 3-year, randomized controlled study.
Topics: Adult; Aged; Behavior; Cognition; Depression; Female; Humans; Huntington Disease; Male; Middle Aged; | 2007 |
5 other studies available for riluzole and Depression
| Article | Year |
|---|---|
Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Depression; Humans; Male; Mice; Mice, | 2018 |
Pharmacologic Management Strategies in ALS #301.
Topics: Amyotrophic Lateral Sclerosis; Depression; Dyspnea; Guidelines as Topic; Humans; Muscle Spasticity; | 2016 |
Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole.
Topics: Acetates; Animals; Avoidance Learning; Behavioral Symptoms; Depression; Disease Models, Animal; Food | 2010 |
Targeting glial physiology and glutamate cycling in the treatment of depression.
Topics: Animals; Depression; Disease Models, Animal; Excitatory Amino Acid Antagonists; Glutamic Acid; Human | 2009 |
Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice.
Topics: Administration, Oral; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depression; | 2012 |